Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSpyre reports $741M cash position, suspends at-the-market stock offering program
Filed April 13, 2026 · Period ending April 13, 2026 · ~1 min read
Key Changes
-
high
Preliminary Q1 2026 cash position of ~$741M disclosed, though unaudited and subject to material change when final financials are released.
Item 8.01 verify on EDGAR → -
medium
Company suspended its at-the-market equity offering, halting further stock sales under existing agreement until new registration documents are filed.
Item 8.01 verify on EDGAR → -
medium
Q1 cash includes $30M from legacy asset sales, but $23M of that will be paid to contingent value rights holders in Q2, netting only $7M for operations.
Item 8.01 verify on EDGAR → -
low
No independent accounting firm has reviewed the preliminary cash figures; final Q1 balance sheet amounts may differ materially.
Item 8.01 verify on EDGAR →
Summary
Spyre Therapeutics disclosed a preliminary cash position of approximately $741 million as of March 31, 2026, providing investors an early look at the company's liquidity before formal Q1 earnings. However, the company emphasized these figures are unaudited and could change materially when final financials are released.
The cash total includes $30 million from legacy asset dispositions, though most of that ($23 million) will be paid out to contingent value rights holders next quarter, leaving a net benefit of only $7 million. Simultaneously, Spyre suspended its at-the-market equity offering program by terminating the active prospectus with TD Securities.
While the underlying sales agreement remains in place, the company cannot sell additional shares under this program until it files new registration documents. This suggests Spyre may be comfortable with its current cash runway or is considering alternative financing approaches. Investors should watch for the final Q1 financial results to confirm the preliminary cash figures and monitor whether the company files a new ATM prospectus or pursues other capital-raising strategies.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Spyre disclosed preliminary Q1 2026 cash position of ~$741M, including $30M legacy asset proceeds, with ~$23M payable to CVR holders in Q2.
Added in current filing · verify on EDGAR →
the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026.
The company disclosed preliminary cash, cash equivalents and marketable securities of approximately $741 million as of March 31, 2026. This figure has not been audited and is subject to change upon completion of financial closing procedures.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Effective April 13, 2026, the Company suspended and terminated the prospectus (the “ATM Prospectus”) relating to the sale of its common stock, $0.0001 par value per share (the “Common Stock”) in an “at-the-market” offering pursuant to the terms of the Sales Agreement, dated, September 6, 2024, by and between the Company and TD Securities (USA) LLC (the “Sales Agreement”). As a result, the Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed.
The company terminated the prospectus for its at-the-market equity offering program with TD Securities, effective immediately. This means Spyre cannot sell additional shares under this arrangement until it files new registration documents with the SEC. The underlying Sales Agreement itself remains valid, but no stock sales can occur without an active prospectus.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify